Health-care companies ticked down as traders rotated back into cyclical sectors after relatively benign inflation data.
Roche re-enters gene-sequencing after failed Illumina bid 10 years ago. Genomics and sequencing require AI/ML infrastructure; the move signals biotech consolidation toward data-capable players, reshaping enterprise tech stack and partnership strategies.
Health-care companies ticked down as traders rotated back into cyclical sectors after relatively benign inflation data.
Roche Holdings is pushing forward with a longstanding plan to enter the gene-sequencing business, 10 years after a failed takeover bid for Illumina.
The Food and Drug Administration granted emergency-use authorization to Zoetis for a drug that treats New World screwworm infestations in dogs and puppies.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
Health-care companies rose as traders rotated back into sectors that are less sensitive to shifts in inflation and oil prices.
Health-care companies fell as traders continued to rotate out of a sector beset by growth and regulatory concerns.
Health-care companies ticked down as traders rotated out of defensive sectors into technology companies.
Health-care companies fell as traders rotated out of defensive sectors back into the high-risk tech sector.
Health-care companies fell as traders continued to rotate out of the sector.
Health-care companies ticked down after mixed earnings from Big Pharma companies. Investors rotated out of defensive areas into…
